These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35117909)

  • 1. Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis.
    Wan L; Wang Z; Xue J; Yang H; Zhu Y
    Transl Cancer Res; 2020 Sep; 9(9):5437-5449. PubMed ID: 35117909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
    Front Oncol; 2022; 12():795933. PubMed ID: 35223476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
    Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
    Front Oncol; 2019; 9():1161. PubMed ID: 31750249
    [No Abstract]   [Full Text] [Related]  

  • 4. The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Ke L; Li S; Huang D
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110986. PubMed ID: 37748223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis.
    Cao J; Yang X; Chen S; Wang J; Fan X; Fu S; Yang L
    Transl Oncol; 2022 Jun; 20():101375. PubMed ID: 35339028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis.
    Ning B; Liu Y; Wang M; Li Y; Xu T; Wei Y
    Front Pharmacol; 2022; 13():748674. PubMed ID: 35355708
    [No Abstract]   [Full Text] [Related]  

  • 8. The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis.
    Ke L; Li S; Cui H
    BMC Cancer; 2022 Nov; 22(1):1185. PubMed ID: 36397030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Nan Z; Guoqing W; Xiaoxu Y; Yin M; Xin H; Xue L; Rong W
    Biomed Res Int; 2021; 2021():1780860. PubMed ID: 33791360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis.
    Zhao J; Dong Y; Bai H; Duan J; Wang G; Xu J; Wang J; Wang Z
    J Natl Cancer Cent; 2022 Mar; 2(1):41-49. PubMed ID: 39035215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
    He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Huang T; Chen X; Zhang H; Liang Y; Li L; Wei H; Sun W; Wang Y
    Front Oncol; 2021; 11():706652. PubMed ID: 34395281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
    Meng G; Liu X; Ma T; Lv D; Sun G
    PLoS One; 2022; 17(2):e0263629. PubMed ID: 35113949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis.
    Xiang X; Li Y; Yang X; Guo W; Zhou P
    BMJ Open; 2022 Aug; 12(8):e058692. PubMed ID: 35926995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients.
    Cao D; Xu H; Xu X; Guo T; Ge W
    Oncoimmunology; 2019; 8(9):e1629258. PubMed ID: 31428527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis.
    Wu RY; Wang BC; Wang K; Xia F; Zhang ZY; Wan JF; Zhang Z
    Front Oncol; 2022; 12():994276. PubMed ID: 36741738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.